Medivo raises $15M for mobile health; GenMark scales back revenue guidance;

@FierceMedDev: Exact raising $63.7M on rocky road to FDA approval. News | Follow @FierceMedDev

@DamianFierce: Medtronic's Infuse no better than graft procedure but more dangerous, according to independent reviews. More | Follow @DamianFierce

@MichaelGFierce: Check out our new FierceBiotech LinkedIn page... and sign up to join the discussion! LinkedIn group page | Follow @MichaelGFierce

> Medical app producer Medivo picked up $15 million in venture cash to support its patient-engagement technology, bringing its total fundraising to $22 million. News

> Sorin won CE mark approval for its Reply 200 line of pacemakers, which are outfitted with technology to monitor sleep apnea. More

> LabCorp ($LH) has signed on to distribute Roche's ($RHHBY) freshly FDA approved viral load test for hepatitis C. Item

> GenMark Diagnostics ($GMNK) has scaled back its annual revenue projections to $30 million from a previously announced $35 million. Release

> Renal denervation devices may have significantly reduced blood pressure in clinical trials, but, in real-world results, the effects were less impressive. Article

Biotech News

@FierceBiotech: Analysis: Big Pharma R&D demonstrates a woeful lack of innovation. News | Follow @FierceBiotech

 @JohnCFierce: AOP spins off its 80% stake in Activartis (cancer vaccines) after Elan shareholders reject takeover bid. Release | Follow @JohnCFierce

@RyanMFierce: In $247M Transition deal, Eli Lilly is reeling in a diabetes drug candidate that it had spun off (sort of): Yesterday's item | Follow @RyanMFierce

> R&D cutbacks loom at Millennium's Cambridge ops. Item

> Teva Pharma breaks M&A silence with bite-sized MicroDose buyout. Report

> AstraZeneca picks Cambridge site as ground zero for R&D reinvention. News

> Royalty's $8B offer wilts after Elan prevails in blocking bid. Article

Pharma News

@FiercePharma: Valeant to sell $2B worth of stock to finance Bausch + Lomb buyout, plus issue $7.5B in debt. More | Follow @FiercePharma

@EricPFierce: India's Roselabs sees lots of upside in prefilled syringes for the Indian market. Story | Follow @EricPFierce

@CarlyHFierce: Bristol-Myers makes another emerging markets move with Simcere partnership in China. Yesterday's story | Follow @CarlyHFierce

> Who wins after SCOTUS pay-for-delay decision? Lawyers. More

> Want a raise, pharma reps? Get into biotech sales instead. Story

Biotech Research News

 @EmilyMFierce: Have you joined the @FierceBiotech LinkedIn group yet? Connect with biotech colleagues and join the discussion: Join now | Follow @EmilyMFierce

> Breast cancer cell growth thwarted by osteoporosis drug in preclinical studies. Report

> New genetic mutations found in families with early-onset Alzheimer's. Item

> Inovio says H7N9 bird flu vaccine effective in mice. Story

> Report: Genomics industry contributed $1 trillion to U.S. economy in last 25 years. More

Pharma Manufacturing News

> French plant part of proposed GSK, Aspen deal. Item

> Roselabs taps growth of prefilled syringe in India. Report

> City forecloses on Indiana insulin plant it helped fund. Article

> Eisai adding packaging facility to U.K. plant. More

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.